Aligos Therapeutics Inc
NASDAQ:ALGS
US |
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
|
US |
Estee Lauder Companies Inc
NYSE:EL
|
Consumer products
|
|
US |
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
|
US |
Church & Dwight Co Inc
NYSE:CHD
|
Consumer products
|
|
US |
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
|
US |
American Express Co
NYSE:AXP
|
Financial Services
|
|
US |
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
|
US |
Visa Inc
NYSE:V
|
Technology
|
|
CN |
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
|
US |
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
|
US |
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
|
US |
Coca-Cola Co
NYSE:KO
|
Beverages
|
|
US |
Target Corp
NYSE:TGT
|
Retail
|
|
US |
Walt Disney Co
NYSE:DIS
|
Media
|
|
US |
Mueller Industries Inc
NYSE:MLI
|
Machinery
|
|
US |
PayPal Holdings Inc
NASDAQ:PYPL
|
Technology
|
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
52 Week Range |
6.89
28.25
|
Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
Johnson & Johnson
NYSE:JNJ
|
US | |
Estee Lauder Companies Inc
NYSE:EL
|
US | |
Exxon Mobil Corp
NYSE:XOM
|
US | |
Church & Dwight Co Inc
NYSE:CHD
|
US | |
Pfizer Inc
NYSE:PFE
|
US | |
American Express Co
NYSE:AXP
|
US | |
Nike Inc
NYSE:NKE
|
US | |
Visa Inc
NYSE:V
|
US | |
Alibaba Group Holding Ltd
NYSE:BABA
|
CN | |
3M Co
NYSE:MMM
|
US | |
JPMorgan Chase & Co
NYSE:JPM
|
US | |
Coca-Cola Co
NYSE:KO
|
US | |
Target Corp
NYSE:TGT
|
US | |
Walt Disney Co
NYSE:DIS
|
US | |
Mueller Industries Inc
NYSE:MLI
|
US | |
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
This alert will be permanently deleted.
Intrinsic Value
The intrinsic value of one ALGS stock under the Base Case scenario is 10.9774 USD. Compared to the current market price of 18.8901 USD, Aligos Therapeutics Inc is Overvalued by 42%.
The Intrinsic Value is calculated as the average of DCF and Relative values:
Valuation Backtest
Aligos Therapeutics Inc
Uncover deeper insights with the Valuation Backtest. Learn how current stock valuations stack up against historical averages to gauge true investment potential.
Start backtest now and learn if your stock is truly undervalued or overvalued!
Stock is trading at its lowest valuation over the past 5 years.
To access the results of this valuation backtest, please register an account with us. Registration is quick and gives you instant access to insights on 3 stocks per week for free.
The backtest for ALGS cannot be conducted due to limitations such as insufficient data or other constraints. Please select a different stock or adjust your settings.
Fundamental Analysis
Select up to 3 indicators:
Select up to 3 indicators:
Months
Months
Months
Months
Select up to 2 periods:
Revenue & Expenses Breakdown
Aligos Therapeutics Inc
Balance Sheet Decomposition
Aligos Therapeutics Inc
Current Assets | 99.6m |
Cash & Short-Term Investments | 94.5m |
Other Current Assets | 5m |
Non-Current Assets | 9.2m |
PP&E | 8.6m |
Other Non-Current Assets | 631k |
Current Liabilities | 23.6m |
Accounts Payable | 6.8m |
Accrued Liabilities | 12.7m |
Other Current Liabilities | 4m |
Non-Current Liabilities | 18m |
Long-Term Debt | 203k |
Other Non-Current Liabilities | 17.8m |
Earnings Waterfall
Aligos Therapeutics Inc
Revenue
|
8m
USD
|
Operating Expenses
|
-101.5m
USD
|
Operating Income
|
-93.5m
USD
|
Other Expenses
|
17.8m
USD
|
Net Income
|
-75.7m
USD
|
Free Cash Flow Analysis
Aligos Therapeutics Inc
USD | |
Free Cash Flow | USD |
ALGS Profitability Score
Profitability Due Diligence
Aligos Therapeutics Inc's profitability score is 18/100. The higher the profitability score, the more profitable the company is.
Score
Aligos Therapeutics Inc's profitability score is 18/100. The higher the profitability score, the more profitable the company is.
ALGS Solvency Score
Solvency Due Diligence
Aligos Therapeutics Inc's solvency score is 64/100. The higher the solvency score, the more solvent the company is.
Score
Aligos Therapeutics Inc's solvency score is 64/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
ALGS Price Targets Summary
Aligos Therapeutics Inc
According to Wall Street analysts, the average 1-year price target for ALGS is 105.4 USD with a low forecast of 60.6 USD and a high forecast of 183.75 USD.
Dividends
Current shareholder yield for ALGS is .
Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?
Profile
Country
Industry
Market Cap
Dividend Yield
Description
Aligos Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which is engaged in in developing therapeutics for chronic liver diseases and viral infections. The company is headquartered in South San Francisco, California and currently employs 93 full-time employees. The company went IPO on 2020-10-16. The firm is focused on developing therapeutics to address unmet medical needs in viral and liver diseases. The company uses its oligonucleotide and small molecule platforms to develop pharmacologically optimized drug candidates for use in combination regimens. The company is initially focused on developing functional cure for Chronic Hepatitis B (CHB); cirrhosis, end-stage liver disease (ESLD) and hepatocellular carcinoma (HCC). The company developing a portfolio of differentiated drug candidates for CHB, including an S-antigen Transport-inhibiting Oligonucleotide Polymers (STOPS) molecule, a small molecule Capsid Assembly Modulator (CAM), and oligonucleotides, such as ASO and Small interfering RNA (siRNA), each of which is designed against targets in the Hepatitis B Virus (HBV) life cycle. The firm's pipeline includes ALG-010133, ALG-000184, ALG-020572, ALG-125097 and ALG-055009.
Contact
IPO
Employees
Officers
The intrinsic value of one ALGS stock under the Base Case scenario is 10.9774 USD.
Compared to the current market price of 18.8901 USD, Aligos Therapeutics Inc is Overvalued by 42%.